FDA completes inspection of Indoco’s API manufacturing facility at Patalganga with zero observations
The inspection concluded with zero form 483 observations
The inspection concluded with zero form 483 observations
The inspection was carried out between May 26, 2025 and May 31, 2025
This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
NewCo’s pipeline includes five investigational medicines
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
The inspection was conducted from July 22-25, 2025
Subscribe To Our Newsletter & Stay Updated